They say that timing is everything, and it’s especially true when launching a new business.
In 2018, Wall Street veteran and serial entrepreneur Evan Gappelberg founded Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF) on the idea that augmented reality (AR) and 3D modelling would become of central importance to e-commerce.
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF) has announced a series of new deals and renewals for its flagship product, ARitize3D, which is driving the company's growth.
The company said it has successfully delivered over 37,700 3D models to its customers in various eCommerce industries, positioning itself for further expansion as more merchants transition from 2D flat photos to immersive 3D experiences.
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF) has closed the $A10 million cornerstone investment by prominent Western Australian explorer De Grey Mining Ltd after receiving the green light from the Toronto Stock Exchange.
The TSX has notified Novo that it has accepted notice of the financing and provided conditional approval of the listing of the shares issued under the financing.
Imugene Ltd (ASX:IMU, OTC:IUGNF) welcomes the extension of a new patent from the United States Patent Office – number 11,684,929 – for its immunotherapeutic asset PD1-Vaxx, which is in development for non-small cell lung cancer (NSCLC).
This extension will now see the patent entitled 'Human PD1 peptide vaccines and uses thereof' expire on February 11, 2040, including 685 days of patent term adjustment added to the original expiry date of March 28, 2038.
PowerTap Hydrogen Capital Corp has announced a non-brokered private placement offering of a minimum of 588,235 units and a maximum of 1,764,706 units, for minimum gross proceeds of C$500,000 and maximum gross proceeds of C$1,500,000. Each unit shall consist of one common share and one half of one common share purchase warrant. Each whole warrant shall entitle the holder to purchase one additional share of the company at a price of $1.15 for a period of two years following the closing of the private placement, subject to an acceleration clause. The company said it intends to use the net proceeds of the private placement for product and manufacturing development; sales and marketing; and G&A. The private placement is expected to close on or before August 7, 2023.
Silver X Mining Inc said it has closed the second of its previously announced non-brokered private placement offering with the placement of 3,006,700 units at a price of $0.30 each for gross proceeds of $902,010. On June 5, 2023, the company announced the closing of the first tranche of the offering with proceeds of $1,263,015. In total, the company has placed 7,216,750 units for aggregate gross proceeds of $2,165,025. The company intends to use the net proceeds from the Offering for capital expenditures and exploration related to the Nueva Recuperada Silver District in Peru and potential acquisitions of assets. Silver X CEO, Jose Garcia, and vice president, Corporate Development, Sebastian Wahl, each participated for a total of approximately $133,000 worth of units in the second tranche of the offering. The company expects to close the final tranche of the offering in early July and has identified additional orders.
Plurilock Security Inc said it has closed the second and final tranche of its previously announced non-brokered private placement of 6,499,688 units of the company at a price of $0.145 per Unit, for aggregate gross proceeds of $942,454.76. The aggregate proceeds raised in both tranches totaled approximately $1,646,805. The company intends to use the proceeds raised from the private placement for general corporate purposes and market awareness advertising. Plurilock also announced that, under the indenture between the company and Computershare Trust Company of Canada dated August 15, 2022, governing the 10% unsecured convertible debentures in the principal amount of $1,245,000 previously issued on August 15, 2022, and the 10% unsecured convertible debentures in the principal amount of $285,000 previously issued on September 20, 2022, the company will issue Shares in satisfaction of interest payments. The company will issue an aggregate of $75,537 worth of shares at the closing market price on June 29, 2023 to holders of the debentures in satisfaction of an aggregate of $75,537 in interest payable as of June 30, 2023. And Plurilock also announced that it intends to amend the exercise price of certain common share purchase warrants originally issued on August 15, 2022, September 20, 2022, December 21, 2022, December 30, 2022 and January 16, 2023. and the conversion price of the debentures all to to 20 cents per share.
Rakovina Therapeutics Inc has released the results of voting at its 2023 annual general meeting of shareholders held on June 28, 2023. All four members of the company's board of directors named as nominees in its management information circular were re-elected as directors: Jeffrey Bacha, Dr Dennis Brown, Alfredo De Lucrezia and Michael Liggett. Additional voting results from the meeting saw shareholders approve the appointment of Davidson & Company LLP as the company's auditor until the next annual meeting; and approve the company's existing omnibus equity incentive plan.
Zoglo's Food Corp said it has appointed Hari Varshney as a director of the company to fill a board vacancy. Varshney is a chartered professional accountant. He has been in the venture capital business since 1985, and has been a director and/or officer of many public companies. After the appointment of Varshney, Henry Ender has resigned as a director of the company effective the end of day of June 27, 2023. Zoglo's said it is actively looking for candidates to fill the casual vacancies.
Immunic Inc has announced its participation in a number of scientific and investor conferences in July. At the 'Symposium 234: Mucosal Immunology – A Translational View into the Clinic’, being held July 6-8, 2023, in Potsdam, Germany, Dr Martina Wirth, manager Translational Pharmacology at Immunic, will present preclinical data and data from the company's phase 1b clinical trial of IMU-856 in celiac disease in an e-poster, and during a poster pitch session. The poster presentation will be available on Immunic's website at: https://ir.imux.com/events-and-presentations. At the SVB Securities Therapeutics Forum, being held in New York from July 11-12, 2023, Dr Daniel Vitt, the company’s chief executive officer and president will participate in one-on-one investor meetings. At the 47th Annual International Herpesvirus Workshop, being held July 15-19, 2023, in Missoula, Montana, Immunic's collaboration partner will present a poster and participate in a satellite workshop at this conference. The poster presentation will also be accessible on Immunic's website at: https://ir.imux.com/events-and-presentations. And at the Immunic's Celiac Disease KOL Roundtable, Immunic's management will be joined by two renowned key opinion leaders to discuss ongoing active celiac disease and its high unmet medical need for new treatment options, in a webcast on Thursday, July 20, 2023, at 8.00am ET. The Celiac Disease KOL Roundtable will be held virtually via Zoom. To participate, interested parties should register in advance at: https://imux.zoom.us/webinar/register/WN_m-d7ddH1SDqFWc7alKSiKA. An archived replay of the webcast will be available on Immunic's website at: https://ir.imux.com/events-and-presentations.
Numinus Wellness Inc has said it will release its financial results for the quarter ended May 31, 2023, after market close on Monday, July 17, 2023. Interested parties are invited to participate in the company's Q3 2023 results conference call and webcast occurring on the same day, at 5.30pm Eastern time / 2,30pm Pacific time. To listen to the live webcast, register at: https://events.q4inc.com/attendee/612414870. The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations. To participate in the live conference call, dial-in details are: 1 (888) 330-3632 (Toll-free North America); 1 (646) 960-0837 (International). A replay of the conference call can also be accessed after 8.30pm Eastern time / 5.30pm Pacific time on July 17, 2023, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until July 31, 2023.
MAS Gold Corp announced that Steven Goldman has resigned as a director of the company effective June 27, 2023. The company thanked Goldman for his valuable contributions and wishes him every success in his future endeavours.
Cardiol Therapeutics Inc announced the results from its annual general meeting (AGM) held virtually through live audio webcast where its shareholders voted in favor of all management resolutions. The Canadian clinical-stage life sciences company focused on the development of therapies for the treatment of heart disease, said that David Elsley, Peter Pekos, Dr Guillermo Torre-Amione, Colin Stott, Michael Willner, Jennifer Chao, Chris Waddick, Teri Loxam were all elected as directors for the ensuing year. The shareholders also approved the appointment of BDO Canada LLP as auditors until the next AGM and the authorized the directors to fix the remuneration to be paid to the auditors.